A retrospective analysis of growth hormone therapy in children with Schaaf–Yang syndrome

Nils R. Hebach | Pilar Caro | Bailey A. Martin-Giacalone
Philip J. Lupo | Felix Marbach | Daniela Choukair
Christian Patrick Schaaf

1Institute of Human Genetics, Heidelberg University, Heidelberg, Germany
2Department of Pediatrics Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA
3Division of Paediatric Endocrinology and Diabetology, University Children’s Hospital, Heidelberg, Germany
4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

Correspondence
Christian Patrick Schaaf, Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, D-69120 Heidelberg, Germany.
Email: christian.schaaf@med.uni-heidelberg.de

Abstract
Short stature is a common phenotype in children with Schaaf–Yang syndrome (SYS). Prader–Willi syndrome (PWS) and SYS share several phenotypic features including short stature, muscular hypotonia and developmental delay/intellectual disability. Evidence exists that similar to PWS, growth hormone (GH) deficiency may also be a feature of SYS. Recombinant human GH (rhGH) therapy has been approved for PWS, but the effects of rhGH therapy in individuals with SYS have not yet been documented. This retrospective, questionnaire-based study analyzes the prevalence of rhGH therapy in children with SYS, the effects of rhGH therapy on anthropometric measures, and parental perception of the treatment. Twenty-six individuals with SYS were sent a clinical questionnaire and a request for growth charts. We found a significant increase in height z-score \((p^* = 0.04)\) as well as a significant decrease in body mass index 6 months after rhGH therapy initiation \((p^* = 0.04)\). Furthermore, height z-scores of the treated group (mean z-score = –1.00) were significantly higher than those of the untreated group (mean z-score = –3.36, \(p = 0.01)\) at time of enrollment. All parents reported an increase in muscle strength and endurance, and several families noted beneficial effects such as improved cognition and motor development.

KEYWORDS
clinical genetics, neurodevelopmental disorder, pediatric endocrinology, rare disease

1 | INTRODUCTION

Schaaf–Yang syndrome (SYS, OMIM # 615547) is a rare autosomal-dominant, imprinted genetic disorder, caused by truncating variants of the MAGEL2 gene. MAGEL2 is located within the Prader–Willi critical region on chromosome 15. While Prader–Willi syndrome (PWS, OMIM #176270, PWS) is typically caused by the deletion of paternal chromosome 15q11-q13 or maternal uniparental disomy of chromosome 15, SYS is caused by truncating point mutations of the paternal copy of MAGEL2, one of the protein-coding genes within the PWS critical region.

SYS was initially termed “Prader–Willi like syndrome” due to an overlap in the phenotype between SYS and PWS.\(^1\) This phenotypic overlap includes hypotonia, developmental delay (DD)/intellectual disability (ID) and short stature. However, as the cohort of SYS increased, it became more apparent that the phenotypes of the two syndromes were clinically distinct: The prevalence of autism spectrum disorder (ASD) and joint contractures is significantly higher in SYS in comparison to PWS.\(^2\)–\(^5\) Furthermore, profound hyperphagia and morbid obesity appear to be less prevalent in SYS\(^5\)\(^6\) or may manifest later in life.\(^7\)

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.
The MAGEL2 gene encodes for a regulator protein of E3 ubiquitin ligase and affects retromer endosomal protein recycling. It is highly expressed in the central nervous system, especially within the hypothalamus. This has led to endocrinological assessments of individuals with SYS, indicating that similarly to PWS, growth hormone (GH) deficiency is a feature of SYS.

For PWS, recombinant-human growth hormone (rhGH) therapy has been FDA-approved since 2000. It has been shown that in PWS, rhGH therapy not only significantly increases body height, but also improves body composition by decreasing fat mass and increasing lean body mass. More recent studies have shown benefits regarding mental and motor development, as well as an improvement in overall cognition. Adverse events reported during rhGH therapy in PWS include worsening of sleep apnea, respiratory tract infections and peripheral oedema. rhGH therapy is contraindicated in patients with PWS who are “severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment.”

The strong positive effect of rhGH therapy in individuals with PWS poses the question whether rhGH therapy may be a suitable treatment for individuals with SYS. Apart from one case study, rhGH therapy in SYS has not yet been reported in the literature.

Here, we present the effects of rhGH therapy in 14 individuals with SYS and compare them to 12 untreated individuals. Our study provides evidence of a positive effect of rhGH therapy in SYS regarding body height and body composition, as well as subjective improvements of motor ability and cognition.

2 SUBJECTS AND METHODS

2.1 Subjects

To this date, 136 individuals with nonsense and frameshift mutations in MAGEL2 have been included in our SYS registry. From this cohort, all eligible patients were contacted by the research coordinator via email to inform them of the study. Additionally, the research study was announced in the closed Facebook group for SYS. Inclusion criterion was a previously identified truncating variant in MAGEL2. There were no exclusion criteria. Families were sent a consent form, a clinical questionnaire (MAGEL2 Growth Hormone Fillable Questionnaire, Supporting Information), and were asked for growth charts of the affected patients. The study was approved by the Institutional Review Board at Baylor College of Medicine.

2.2 Methods

Information on muscle strength, endurance and satisfaction was measured on a 5-level Likert scale. Height and body mass index (BMI) z-scores (defined as the SD from average height or BMI compared to children of the same sex and age) were calculated using WHO/CDC data and the PedZ calculator (https://www.pedz.de/en/bmi.html).

Since height, weight, and BMI were collected at various time points within the treated group, we estimated the values at 90 and 180 days after treatment start. These values were calculated using linear interpolation within the R zoo package v1.8-8. The predictor was defined as 0, 90, or 180 days following treatment (categorical).

Data were approximately normally distributed for change in height and BMI z-scores. Therefore, to detect a difference in height or BMI z-scores based on the time since treatment start, we conducted a repeated measures analysis of variance (ANOVA) with a Greenhouse–Geisser correction. We then performed post-hoc paired t tests with a Bonferroni correction to assess pairwise statistical differences.

Anthropometric measures at birth were compared to the general population using the one-sample Wilcoxon test. In order to compare anthropometric measurements as well as sex and age distribution between the treated and untreated groups, we performed Mann-Whitney U tests. Effect size of Mann-Whitney U tests were calculated using the R companion package v2.3.27 and reported according to Fritz et al.

Statistical significance was determined as p < 0.05. All statistical analyses were carried out using R v4.0.4.

3 RESULTS

3.1 Prevalence of GH Therapy

In this sample, 14 of 26 individuals with SYS (54%) were on rhGH therapy. There were no significant differences between the two groups regarding age and sex distribution (Figure 1A,B). However, males were overrepresented in the treatment group (64%, 9 out of 14) and underrepresented in the untreated group (33%, 4 out of 12). The clinical phenotype between the two groups was also similar (Figure 1C). Detailed growth charts were available for 16 of the children (11 treated, 5 untreated, Figures 2 and S1).

The average age of rhGH therapy initiation was 2.72 years (range 0.42–8.0 years) and the average treatment duration was 3.07 years (range 0.38–15.78 years). No patient had to interrupt or discontinue rhGH therapy. The average dose administered was 0.23 mg rhGH/kg bodyweight/week (SD 0.09), similar to the recommended dose for PWS which is 0.24 mg rhGH/kg bodyweight/week.

3.2 Pre-treatment assessment

We were able to collect information from 16 patients (13 treated, 3 untreated) on endocrinological assessments prior to treatment (Table 1).

IGF-1 level measurement is the most common test (75%) prior to treatment in our sample, followed by IGF-BP3 level measurement in 44% of all individuals. Stimulation tests (either with clonidine [STH] or arginine) were performed in only 25% of all kids. Bone mineral density...
FIGURE 1  Comparison of the treated and untreated group. (A) Age in years of the untreated group and the treated group. (B) Composition of the untreated and the treated group by sex. (C) Prevalence of conditions associated with Schaaf–Yang syndrome (SYS) phenotype in the treated and untreated group [Colour figure can be viewed at wileyonlinelibrary.com]

FIGURE 2  Growth progression of individuals with Schaaf–Yang syndrome: All available growth charts, plotted with variable x axes for better readability [Colour figure can be viewed at wileyonlinelibrary.com]
measurements and acid-labile subunit tests are also less common. Only one patient has reported not to have had a pre-treatment assessment. rhGH therapy was justified with his short stature alone.

### 3.3 | Growth progression of individuals with SYS

In this sample, the children with SYS were born within the normal height, weight and BMI range (one-sample Wilcoxon tests; \( p = 0.87, p = 0.06, p = 0.08 \) respectively). There were no significant differences in height z-score between the treated and untreated group in this study at birth (\( p = 0.71 \), Figure 3A). Only 4 (2 in the untreated group and 2 in the treated group) out of 26 individuals in total had a height z-score below \(-2\) at birth, meeting the CDC criterion for short stature (15%).

At an age of 6 months, 8 of the 16 individuals with detailed growth charts (50%) had already had a height z-score below \(-2\). At an age of 3 years, all 16 individuals (100%) had a height z-score below \(-2\) (Figure S2).

Similarly, at time of enrollment in this study, only 2 out of the 12 untreated individuals had a height z-score above \(+2\). The other 10 untreated children (83%) met the CDC criterion for short stature.

### 3.4 | Effects of rhGH therapy on height

Comparing height z-scores of all treated individuals to all untreated individuals at time of enrollment in this study, there was a significant difference in height z-scores (Mann–Whitney U test, \( p = 0.01 \)) (Figure 3B and Table 2). The effect size \( r = 0.51 \), indicating that rhGH treatment had a large effect on height z-score.

Eight of the 14 patients on rhGH treatment had sufficient data for a more detailed analysis of the effect of rhGH on height z-score during the first 6 months of treatment. The mean height z-score at the start of treatment initiation was \(-2.6\) and increased to \(-2.1\) and \(-1.7\) after three and 6 months of treatment respectively. A repeated measures ANOVA with Greenhouse–Geisser correction determined that height z-score differences between time points were statistically significant (\( F = 9.97, p = 0.02 \)). Post-hoc paired t tests with a Bonferroni correction further confirmed the significant increase in height z-score over the timespan of 6 months (\( p^* = 0.04 \)) as well as a significant increase from month 3 to month 6 (\( p^* = 0.02 \)). The increase in height z-score from treatment start to 3 months was not significant (\( p^* = 0.10 \)) (Figure 3C,D).

### 3.5 | Effects of rhGH therapy on body composition

BMI z-scores were used as a surrogate parameter of body composition. Seven of the 14 individuals on rhGH treatment had sufficient data for a more detailed analysis of the effect of rhGH on BMI z-score during the first 6 months of treatment. The mean BMI z-score at the start of treatment initiation was 1.3 and decreased to 0.9 and 0.7 after

---

**TABLE 1**

| Patients | rGH treatment w/o treatment | w/o treatment | n/N | % Diagnostic tests 1 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 |
|----------|----------------------------|--------------|-----|-----------------------|
| IGF-1    | X                          | X            | X   | X                     |
| IGF3-BP  | X                          | X            | X   | X                     |
| Stimulation test | X | X | X | X |
| Bone mineral density | X | X | X | X |
| ALS      | X                          | X            | X   | X                     |

Note: Stimulation test performed either with clonidine (STH) or arginine. Abbreviations: ALS, acid-labile subunit test; rhGH, recombinant human GH.
three and 6 months of treatment respectively. The statistical analysis was identical to the analysis performed for height z-score. Here, BMI z-score change was also significant (repeated measures ANOVA with Greenhouse–Geisser correction: $F = 10.71$, $p = 0.01$). Post-hoc paired $t$ tests were only significant for the full observation period of 6 months ($p^* = 0.04$) (Figure 4C,D). Likewise, weight for stature (WFS) z-scores decreased from 1.0 to 0.6 and 0.2 after three and 6 months of treatment respectively (Figure S3).

However, there were no significant differences in BMI z-scores between the treated and untreated group neither at birth...
nor at time of enrollment (Figure 4A, B). Furthermore, there was no significant difference in weight z-score change of the treated group between time points (repeated measures ANOVA with Greenhouse–Geisser correction: $F = 0.13$, $p = 0.73$, Figure S4).

3.6 | Subjective effects of rhGH therapy

Parental perception of changes after the onset of treatment was unanimously positive: All families noted either an increase (seven patients) or strong increase (six patients) in muscle strength. For endurance, feedback was exactly the same. Overall, general satisfaction with the treatment was high, with eight families stating they were very satisfied, three families stating they were satisfied and two families being neutral (Figure 5). Additional reported benefits were improved cognitive and social skills (six patients) and improved motor development (five patients).

3.7 | Adverse events of rhGH therapy

During the time-span of rhGH treatment, worsening of sleep apnoea in one individual and worsening of scoliosis/kyphosis in further two individuals was reported. These events did not require any intervention or alteration of rhGH treatment. In both cases of scoliosis, treatment start coincided with local Covid19 restrictions, and physical therapy and new back braces were no longer accessible for both patients.

4 | Discussion

4.1 | GH deficiency is the likely cause for short stature in children with SYS

In this population of individuals with SYS, children were born within normal height z-score range, which is, in fact, unsurprising, because
fetal growth is considered to be independent of pituitary GH secretion. However, the onset of growth retardation after birth was rapid and severe: At 6 months of age, 50% of the infants with detailed growth charts had already had a height z-score below -2. This is similar to observations made in infants with congenital GH deficiency, who have a decrease in height z-score by -1.6 in the first 6 months of life and further strengthens the assumption that GH deficiency is responsible for the short stature in children with SYS.

4.2 | rhGH treatment significantly improves Height

In our sample, height z-score increased on average by 0.47 after the first 3 months and by 0.85 after the first 6 months of rhGH therapy. This effect is in line with studies on PWS noting an increase in height z-score of 0.8 after 6 months of treatment, and an increase in height z-score of +1.1 or +1.5 after 1 year of treatment.

4.3 | rhGH treatment may improve body composition

We also found that BMI z-score decreased on average by 0.43 after the first 3 months and by 0.64 after the first 6 months of rhGH therapy. This is similar to previous studies in PWS, which have shown that rhGH therapy decreases the BMI z-score, decreases body fat percentage, and increases lean body mass. In our sample, this decrease in BMI is partially due to the increase in height. To further investigate if the BMI decrease can also be partially attributed to change in body composition, we investigated WFS z-scores: Here, we were also able
to show a decrease by 0.4 after the first 3 months and by 0.8 after
the first 6 months of rhGH therapy. The observed decrease in BMI
z-score with a similar decrease in WFS z-scores and additional individ-
ual parental reports suggest that rhGH therapy has a comparable
effect on body composition in children with SYS. On the other hand,
the effect may not be very pronounced, because we could not find
statistical differences in BMI z-score between the treated and the
untreated group.

In the future, lean body mass should be evaluated directly using
dual-energy X-ray absorptiometry scans. This will give a more accu-
rate insight into the changes of body composition than the surrogate
parameter BMI.

4.4 Adverse events and beneficial side effects

In our sample, adverse events were not severe enough for rhGH treat-
ment to be interrupted or discontinued. Furthermore, sleep apnea and
scoliosis/kyphosis are both common features of SYS.3,7 Our study
was not designed and does not have the power to attribute these
events to the rhGH treatment. Worsening of sleep apnea has also
been reported in the context of rhGH treatment for PWS,20,21,28
which may indicate that the same precautions as for PWS should be
taken when prescribing rhGH to SYS patients.

Beneficial side effects reported by parents in our study were
improved motor development and improved social skills. The impact
of rhGH therapy on ASD phenotypic severity and developmental
milestones should be assessed more systematically in the future.

4.5 Time of treatment start

For PWS, recommendations are to start rhGH therapy as early as
between 6 and 12 months of age,29 and definitely before the onset of
obesity, which often begins at 2 years of age.30 As rhGH has been
shown to improve motor developmental and cognitive skills17–19 and
these benefits have also been noted by parents of children with SYS,
there are indications that an early treatment start may not only stop
growth retardation, but may also be beneficial for the child’s
development.

4.6 Limitations and strengths

Our study must be considered in the light of some limitations. First,
this study is a retrospective, questionnaire-based analysis. However,
we were able to demonstrate that there were no significant differ-
ces regarding age and sex distribution between the treated and the
untreated group and that the phenotypic severity was similar, which
suggests that selection bias due to demographic characteristics was
not likely to play an important role. Furthermore, differences in
anthropomorphic measurements at birth were non-significant. How-
ever, the proportion of individuals with short stature reported here
(100% of individuals at 3 years of age) is significantly larger than the
56% previously reported.11 We expect a recruitment bias favoring
those families whose children have been diagnosed with short stature,
as this study may appear to be more relevant to them, which might
explain the discrepancy. Likewise, while we contacted all families of
children with SYS in our registry, we also expect a recruitment bias
favoring those families whose children received rhGH for much the
same reason.

Furthermore, rhGH therapy is an invasive and time-consuming
treatment requiring daily subcutaneous injections. Therefore, it is pos-
sible that parents who follow through with this treatment are con-
vinced of its beneficial effects and have a high outcome expectation.
Thus, placebo effects may be more pronounced and could exaggerate
the effect of rhGH therapy. Finally, as this was a retrospective study,
recall biases might also enhance effects of rhGH. However, the
anthropometric measurements have been taken before enrollment in
this study and should remain unaffected by recall or observer biases.

Strengths of this study include the similar distribution of the
treated and untreated group, which allows for a direct comparison,
the large study population size, and the detailed growth information
we are able to present.

5 CONCLUSION

Our findings suggest that rhGH therapy should be considered as a
treatment for SYS. In this cohort, it led to an increase of body height
and parental reports suggested an improvement of endurance and
muscle strength. Furthermore, several families also noted additional
beneficial side effects such as improved cognition and motor develop-
ment. These data pave the way for a prospective clinical trial of rhGH
therapy for individuals with SYS.

ACKNOWLEDGMENTS

The authors thank the individuals and the families with SYS, who have
provided clinical data and overwhelming support for our efforts. The
authors further thank pediatricians and endocrinologists who made
growth charts and dosages available to us. The authors would also like
to thank A. Plaza-Gonzalez and J. Siebenlist for proofreading the
manuscript.

CONFLICT OF INTEREST

The authors declare no competing interests.

AUTHOR CONTRIBUTIONS

Nils R. Hebach and Pilar Caro: Performed the study and analyzed the
data. Nils R. Hebach: Designed the questionnaires, generated figures
and wrote the initial version of the manuscript. Pilar Caro: Coordinat-
ed the study and participated in designing the questionnaires. Bai-
ley A. Martin-Giacalone: Performed the statistical analyses and gave
feedback on study endpoints. Philip J. Lupo: Oversaw the statistical
analyses. Felix Marbach: Gave feedback on overall study design and
participated in the questionnaire design. Daniela Choukair: Gave
feedback on the questionnaire design. Christian Patrick Schaaf: Conceived the study, supervised the study and acquired funding. All authors reviewed, edited and approve of the manuscript.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/cge.14000.

DATA AVAILABILITY STATEMENT
Data are available upon reasonable request. Detailed data from clinical questionnaires as well as growth charts analysed during the current study are available from the corresponding author.

ETHICS STATEMENT
This study was approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals, H-34578. Informed consent was obtained from all individuals and their guardians.

ORCID
Nils R. Hebach https://orcid.org/0000-0003-1921-3244
Pilar Caro https://orcid.org/0000-0002-7531-3234
Bailey A. Martin-Giacalone https://orcid.org/0000-0003-0758-8487
Philip J. Lupo https://orcid.org/0000-0003-0978-5863
Felix Marbach https://orcid.org/0000-0003-3953-6235
Daniela Choukair https://orcid.org/0000-0002-1631-3883
Christian Patrick Schaaf https://orcid.org/0000-0002-2148-7490

REFERENCES
1. Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nat Genet. 2013;45(11):1405-1408.
2. Fountain MD, Schaaf CP. Prader-Willi syndrome and Schaaf-Yang syndrome: neurodevelopmental diseases intersecting at the MAGEL2 gene. Diseases. 2016;4(1):2-8.
3. McCarthy J, Lupo PJ, Kovar E, et al. Schaaf-Yang syndrome overview: report of 78 individuals. Am J Med Genet A. 2018;176(12):2564-2574.
4. Thomason MM, McCarthy J, Goin-Kochel RP, Dowell LR, Schaaf CP, Berry LN. Neurocognitive and neurobehavioral phenotype of youth with Schaaf-Yang syndrome. J Autism Dev Disord. 2020;50(7):2491-2500.
5. Fountain MD, Aten E, Cho MT, et al. The phenotypic spectrum of Schaaf-Yang syndrome: 18 affected individuals from 14 families. Genet Med. 2017;19(1):45-52.
6. Miller JL, Lynn CH, Driscoll DC, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A(5):1040-1049.
7. Marbach F, Elgizouli M, Rech M, et al. The adult phenotype of Schaaf-Yang syndrome. Orphanet J Rare Dis. 2020;15(1):294.
8. Tacer KF, Potts PR. Cellular and disease functions of the Prader-Willi syndrome gene MAGEL2. Biochem J. 2017;474(13):2177-2190.
9. Hao YH, Fountain MD Jr, Fon Tacer K, et al. USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder. Mol Cell. 2015;59(6):956-969.
10. Gregory LC, Shah P, Sanner JRF, et al. Mutations in MAGEL2 and L1CAM are associated with congenital hypotuitarism and arthrogryposis. J Clin Endocrinol Metab. 2019;104(12):5737-5750.
11. McCarthy JM, McCann-Crosby BM, Rech ME, et al. Hormonal, metabolic and skeletal phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome. J Med Genet. 2018;55(5):307-315.
12. Eiholzer U, Weber R, Stutz K, et al. Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome. Acta Paediatr Suppl. 1997;423:66-68.
13. Lindgren AC, Hagenes L, Muller J, et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr. 1998;87(1):28-31.
14. de Lind van Wijngaarden RF, Siemensma EP, Festen DA, et al. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94(11):4205-4215.
15. Yang A, Choi JH, Sohn YB, et al. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial. Orphanet J Rare Dis. 2019;14(1):216.
16. Moris A, Jennifer AM, Alberto P, Vlady O, Nicky K, Maithe T. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study. Int J Pediatr Endocrinol. 2020;2020(1):20-20.
17. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2008;68(6):919-925.
18. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145(6):744-749.
19. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97(7):2307-2314.
20. Bakker NE, Lindberg A, Heissler J, et al. Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS database. J Clin Endocrinol Metab. 2017;102(5):1702-1711.
21. de Gouveia Buff PC, Rocha FR, Sakura IS, et al. Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open. 2020;4(1):e000630.
22. Genotropin [Prescribing Information]. Pharmacia and Upjohn Company LLC. 04/2019.
23. Eight years of growth hormone treatment in a patient with Schaaf-Yang Syndrome. 58th Annual ESPE; 2019. European Society for Paediatric Endocrinology.
24. Fritz CO, Morris PE, Richter JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Child Psychol. 2012;141(1):2-18.
25. Mehta A, Hindmarsh PC, Stanhope RG, et al. The role of growth hormone in determining birth size and early postnatal growth, using congenital growth hormone deficiency (GHD) as a model. Clin Endocrinol (Oxf). 2005;63(2):223-231.
26. Pena-Almazan S, Buchlis J, Miller S, Shine B, MacGillivray M. Linear growth characteristics of congenitally GH-deficient infants from birth to one year of age. J Clin Endocrinol Metab. 2001;86(12):5691-5694.
27. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(5):2206-2212.
28. Berini J, Spica Russotto V, Castelnuovo P, et al. Growth hormone therapy and respiratory disorders: long-term follow-up in PWS children. *J Clin Endocrinol Metab*. 2013;98(9):E1516-E1523.

29. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M, speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. *J Clin Endocrinol Metab*. 2008;93(11):4183-4197.

30. Deal CL, Tony M, Hoybye C, et al. Growth Hormone Research Society Workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. *J Clin Endocrinol Metab*. 2013;98(6):E1072-E1087.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Hebach NR, Caro P, Martin-Giacalone BA, et al. A retrospective analysis of growth hormone therapy in children with Schaaf–Yang syndrome. *Clinical Genetics*. 2021;1-10. [https://doi.org/10.1111/cge.14000](https://doi.org/10.1111/cge.14000)